Patents by Inventor Christian S. Hinrichs

Christian S. Hinrichs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11440963
    Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 13, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
  • Patent number: 11434272
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11376318
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: July 5, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11352410
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for Kita-Kyushu Lung Cancer Antigen 152-60 (KK-LC-152-60). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: June 7, 2022
    Assignee: The United States of American, as represented by the Secretary, Department of Health and Human Service
    Inventors: Sanja Stevanovic, Christian S. Hinrichs
  • Patent number: 11338032
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 24, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11331385
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 17, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210338795
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210338797
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210338796
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11077182
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: August 3, 2021
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210130432
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 6, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210130433
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 6, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210121559
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: December 7, 2020
    Publication date: April 29, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20210052647
    Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: February 7, 2019
    Publication date: February 25, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Benjamin Y. Jin
  • Patent number: 10913785
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 9, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 10870687
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: December 22, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Service
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20200062849
    Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
    Type: Application
    Filed: May 8, 2018
    Publication date: February 27, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
  • Publication number: 20190309043
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 10, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 10329339
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: June 25, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20190135891
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for Kita-Kyushu Lung Cancer Antigen 152-60 (KK-LC-152-60). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: April 17, 2017
    Publication date: May 9, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Sanja Stevanovic, Christian S. Hinrichs